Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523366 | 0.94 | F2 (0.34) | F2SLC6A9DDR1BDKRB1CACNA2D1 | |
| SCHEMBL3405557 | 0.88 | UTS2R (0.35) | F2SLC6A9CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL6521493 | 0.87 | F2 (0.37) | F2SLC6A9DDR1HRH3GRIA2 | |
| SCHEMBL3409864 | 0.86 | F2 (0.38) | F2SLC6A9DDR1HRH3GRIA2 | |
| SCHEMBL3405699 | 0.86 | BACE1 (0.41) | F2SLC6A9HRH3BACE1 | |
| SCHEMBL3404007 | 0.85 | ACKR3 (0.37) | F2DGAT2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL3401743 | 0.85 | BACE1 (0.37) | F2DGAT2BACE1 | |
| SCHEMBL3403098 | 0.84 | BACE1 (0.36) | F2DGAT2SLC6A9DDR1CACNA2D1 | |
| SCHEMBL3408137 | 0.84 | DDR1 (0.36) | F2DDR1BDKRB1 | |
| SCHEMBL3403100 | 0.84 | BACE1 (0.38) | F2DDR1TP53BACE1CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | claimed |
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | QDPR, NHERF1, GABRR1 | F2 1098/4885DGAT2 3208/4885SLC6A9 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.